What is claimed is:

## 1. A compound of the formula (I):

$$R_2$$
 $R_1$ 
 $R_1$ 
 $R_2$ 
 $R_1$ 

wherein

5

10

- (i) X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative, or
- (ii) X represents C-CF<sub>3</sub>, Z represents CH, and Y represents nitrogen, forming a 4-trifluoromethylpyridine derivative, or
- (iii) Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and

wherein R<sub>1</sub> and R<sub>2</sub> are each, independently, selected from a group A consisting of

$$R_3$$
 $CH_3$ 
 $R_4$ 
 $R_4$ 
 $R_4$ 
 $R_4$ 

or from a group B, consisting of aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl-C<sub>1</sub>-C<sub>6</sub>-alkoxy, heteroaryl-C<sub>1</sub>-C<sub>6</sub>-alkoxy, aryloxy-C<sub>2</sub>-C<sub>6</sub>-alkoxy, heteroaryloxy-C<sub>2</sub>-C<sub>6</sub>-alkoxy, 1-indanyloxy, 2-indanyloxy, aryloxy, heteroaryloxy, arylthio, heteroarylthio, C<sub>5</sub>-C<sub>6</sub>-cycloalkylthio, C<sub>5</sub>-C<sub>8</sub>-alkoxy, C<sub>5</sub>-C<sub>8</sub>-alkylthio, C<sub>3</sub>-C<sub>6</sub>-alkynyloxy, C<sub>3</sub>-C<sub>6</sub>-alkenyloxy, fluoro-C<sub>2</sub>-C<sub>4</sub>-alkoxy, C<sub>4</sub>-C<sub>8</sub>-cycloalkyloxy, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, halogen, aryl-C<sub>1</sub>-C<sub>4</sub>-alkylthio, heteroaryl-C<sub>1</sub>-C<sub>4</sub>-alkylthio, aryl-C<sub>1</sub>-C<sub>4</sub>-alkylamino, heteroaryl-C<sub>1</sub>-C<sub>4</sub>-alkylamino, heteroaryl and aryl;

with the proviso that:

(i)  $R_1$  and  $R_2$  are different and are not both selected from group A or group B at the same time;

- (ii) when both X and Z are CH and Y is N in formula (I), forming a pyridine derivative, and  $R_1$  is 1-piperazinyl or 4-methylpiperazin-1-yl, then  $R_2$  is other than 2-phenylethyl, benzyloxy, benzylamino, phenylthio, phenoxy, substituted phenoxy,  $C_4$ - $C_8$ -cycloalkyloxy and  $C_3$ - $C_8$ -cycloalkylmethoxy;
- (iii) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and  $R_2$  is 1-piperazinyl, then  $R_1$  is other than phenoxy, phenyl or phenyl substituted by bromo, and  $C_5$ - $C_8$  alkoxy; and when  $R_2$  is 4-methylpiperazin-1-yl or 4-(2-hydroxyethyl)piperazin-1-yl, then  $R_1$  is other than 5-nitro-2-furyl;
- (iv) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and  $R_1$  is 1-piperazinyl, then  $R_2$  is other than  $C_5$ - $C_8$  alkoxy; and where  $R_3$  is H or  $C_{1-4}$ -alkyl, allyl, 2-hydroxyethyl, 2-cyanoethyl, or a nitrogen protecting group, or a prodrug moiety;

 $R_4$  is hydrogen, or  $C_{1-4}$  alkyl;

5

10

15

20

and wherein any aryl or heteroaryl residue, alone or as part of another group, in  $R_1$  or  $R_2$  may be independently substituted in one or more positions, by  $C_{1-4}$ -alkyl,  $C_{1-4}$ -alkoxy,  $C_{1-4}$ -alkylthio,  $C_{2-4}$ -acyl,  $C_{1-4}$ -alkylsulphonyl, cyano, nitro, hydroxy,  $C_{2-6}$ -alkenyl,  $C_{2-6}$ -alkynyl, fluoromethyl, trifluoromethyl, trifluoromethoxy, halogen, -N( $R_5$ )( $R_6$ ), aryl, aryloxy, arylthio, aryl- $C_{1-4}$ -alkyl, aryl- $C_{2-4}$ -alkenyl, aryl- $C_{2-4}$ -alkynyl, heteroaryl, heteroarylthio or heteroaryl- $C_{1-4}$ -alkyl, aryl- $C_{1-4}$ -alkoxy, aryloxy- $C_{1-4}$ -alkyl, dimethylamino- $C_{2-4}$ -alkoxy; and

wherein any aryl or heteroaryl residue as substituents on aryl or heteroaryl, alone or as part of another group, in  $R_1$  or  $R_2$  in turn may be substituted in one or more postions, independently of each other by  $C_{1-4}$ -alkyl,  $C_{1-4}$ -alkoxy, halogen, trifluoromethyl, cyano, hydroxy or dimethylamino; and

R<sub>5</sub> and R<sub>6</sub> independently of each other are hydrogen, methyl or ethyl, or together with the nitrogen atom to which they are bound form a pyrrolidine, piperazine, morpholine, thiomorpholine or a piperidine ring;

and pharmaceutically acceptable salt, hydrate, geometrical isomer, tautomer, optical isomer, *N*-oxide or prodrug form thereof.

- 2. The compound according to claim 1, wherein X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative.
  - 3. The compound according to claim 1, wherein formula (I) represents a 4-trifluoromethylpyridine derivative.
- 10 4. The compound according to claim 1 wherein Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative.

15

20

5. The compound according to claim 1 wherein  $R_3$  is hydrogen and  $R_1$  or  $R_2$  is selected from

$$R_3$$
 $R_4$ 
 $R_3$ 
 $R_4$ 
 $R_4$ 
 $R_4$ 

6. The compound according to claim 1 wherein  $R_1$  or  $R_2$  is selected from

$$R_3$$
 $R_3$ 
 $R_4$ 
 $R_4$ 


and where R<sub>3</sub> is hydrogen and R<sub>4</sub> is selected from hydrogen, methyl or ethyl.

7. The compound according to claim 1 wherein  $R_1$  or  $R_2$  is

$$\binom{R_3}{N}$$
  $R_4$ 

and where R<sub>3</sub> is hydrogen and R<sub>4</sub> is selected from hydrogen, methyl or ethyl.

8. The compound according to claim 1, wherein  $R_1$  or  $R_2$  is selected from



5

20

- 9. The compound according to claim 1, which is selected from the group consisting of:
- 4-(Benzyloxy)-2-(1-piperazinyl)pyrimidine,
  - 4-[(2-Methoxybenzyl)oxy]-2-(1-piperazinyl)pyrimidine,
  - $\hbox{2-}\{[3\hbox{-}(Benzyloxy)benzyl]oxy\}\hbox{-}4\hbox{-}(1\hbox{-}piperazinyl)pyrimidine,$

and their pharmacologically acceptable salts and solvates.

- 15 10. A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient, together with a pharmaceutically acceptable carrier.
  - 11. A method for the prophylaxis or treatment of a serotonin-related medical condition, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.
    - 12. The method according to claim 11, wherein the medical condition is related to the 5- $HT_{2c}$  receptor.

- 13. The method according to claim 11 wherein the medical condition is an eating disorder.
- 14. The method according to claim 11, wherein the medical condition is obesity.
  - 15. The method according to claim 11, wherein the medical condition a memory disorder.
- 16. The method according to claim 11, wherein the medical condition is a mood disorder.
  - 17. The method according to claim 11, wherein the medical condition is an anxiety disorder.
  - 18. The method according to claim 11, wherein the medical condition is selected from sexual dysfunctions, epilepsy and urinary disorders.

15

20

25

- 19. The method according to claim 11, wherein the medical condition is pain.
- 20. The method according to claim 11, wherein the medical condition is substance abuse.
- 21. The method according to claim 11, wherein the medical condition is schizophrenia.
  - 22. A method of making a compound of claim 1, taking a compound of the following formula:

wherein

5

10

- (i) X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative, or
- (ii) X represents C-CF<sub>3</sub>, Z represents CH, and Y represents nitrogen, forming a 4-trifluoromethylpyridine derivative, or
- (iii) Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and wherein

each Hal is independently a halogen;

- and reacting the compound with one or more chemical reagents in one or more steps to produce a compound of claim 1.
- 23. A method of modulating serotonin in a subject comprising administering to the subject an effective amount of a compound of claim 1.
- 24. A method of modulating 5-HT $_{2c}$  in a subject comprising administering to the subject an effective amount of a compound of claim 1.
- 25. The compound according to claim 1, wherein R<sub>3</sub> is an acyl-or alkoxycarbonyl group forming a cleavable amide or carbamate linkage.